Study guide
7.2 Postmortem Redistribution (PMR), Vd & Toxicological Pharmacokinetics
ABMDI Board Certification Fellow
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Performance Section Mastery & Medicolegal Scene Documentation
1.1 Board Exam Architecture, Scoring, and the Performance Section 1.2 Professional Scene Narrative Drafting & Medical Terminology 1.3 Strategic Investigative Interviewing for Witnesses and Suspects 1.4 Physical, Biological, and Trace Evidence Identification & Prioritization 1.5 The Advanced Skills List: The Official 46-Task Blueprint
2 Chapter 2: Legal Framework, Jurisdiction, and Interagency Coordination
2.1 Medicolegal Systems in the United States & Statutory Authority 2.2 Jurisdictional Boundaries & Federal Interagency Liaison 2.3 Accreditation Standards (NAME, ANAB/ISO 17020, IAC4MR) & Office Operations 2.4 Health Information Privacy (HIPAA § 164.512(g)), Public Records, and Subpoenas 2.5 Reviewing a Death Certification: Cause, Manner, and the Certifier’s Role 2.6 Unique Case Problems and Soliciting Legal Opinions
3 Chapter 3: Scene Leadership, Command Structure, and Processing Protocols
3.1 Incident Command System (ICS) Integration & Scene Leadership 3.2 OSAC ASB Standard 037 Protocols & Scene Security Management 3.3 Forensic Photography, Oblique Lighting, 3D Laser Scanning & Mapping 3.4 Search Methodologies, PPE Tiers & Cross-Contamination Controls 3.5 Masqueraded and Staged Death Scenes 3.6 Media-Sensitive Deaths and Public Information Management
4 Chapter 4: Postmortem Changes, Taphonomy, and PMI Estimation
4.1 Early Postmortem Changes: Algor, Livor, and Rigor Mortis Kinetics 4.2 Decomposition Chemistry, Autolysis, Putrefaction & Specialized Taphonomy 4.3 Forensic Entomology, Insect Succession & ADH/ADD Calculations 4.4 Forensic Anthropology, Skeletal Recovery & Biological Profiling
5 Chapter 5: Mechanical Trauma: Blunt, Sharp, and Ballistic Injuries
5.1 Blunt Force Trauma: Abrasions, Contusions, Lacerations & Skeletal Fractures 5.2 Sharp Force Trauma: Incised, Stab, Chop Wounds & Defensive Patterns 5.3 Firearm Injuries, Range of Fire Determinations & Terminal Ballistics 5.4 Motor Vehicle, Pedestrian Strike & Transportation Incident Dynamics 5.5 Explosion and Blast Injury Deaths
6 Chapter 6: Asphyxial, Environmental, and Thermal Deaths
6.1 Asphyxial Deaths: Hanging, Ligature/Manual Strangulation & Positional Asphyxia 6.2 Drowning Mechanisms, Submersion Injuries & Aquatic Recovery 6.3 Fire Deaths, Inhalation Injuries, COHb/Cyanide & Heat Alterations 6.4 Environmental Extremes: Hypothermia, Hyperthermia, High/Low Voltage Electrical & Lightning Deaths 6.5 Weather-Related and Natural-Disaster Deaths
7 Chapter 7: Forensic Toxicology, Specimen Protocols, and Natural Deaths
7.1 Postmortem Specimen Collection Sites, Anticoagulants & Chain of Custody 7.2 Postmortem Redistribution (PMR), Vd & Toxicological Pharmacokinetics 7.3 Opioids, Fentanyl Analogs, Novel Psychoactive Substances & Screening Limits 7.4 Sudden Unexpected Natural Deaths: Cardiovascular, Cerebrovascular & Pulmonary 7.5 Deaths from Therapeutic Complications and Medical Misadventure 7.6 Deaths from Infectious Causes and Public Health Reporting
8 Chapter 8: Pediatric, Infant, and Vulnerable Population Investigations
8.1 Sudden Unexpected Infant Death (SUID/SUDI) Protocols & CDC Doll Re-enactment 8.2 Abusive Head Trauma (AHT), Non-Accidental Skeletal Injuries & Scalds 8.3 Elder Abuse/Neglect, In-Custody Deaths & Excited Delirium/Restraint Analysis 8.4 Deaths in Extended Care Facilities and Group Homes 8.5 Deaths Caused by Animals and Postmortem Animal Activity
9 Chapter 9: Mass Fatality Management, Ethics, and Expert Testimony
9.1 Mass Fatality Incidents, DMORT Operations & DVI Scientific Identifications 9.2 Family Assistance Centers, Antemortem Records & OSAC ASB Std 038 Next-of-Kin Notifications 9.3 ABMDI Code of Ethics, Supervisory QA Audits & Investigator Resiliency 9.4 Medicolegal Testimony & Evidence Admissibility 9.5 Leadership: Mentoring, Correcting Deficiencies, and Personal Performance Standards 9.6 Serology, Bloodstain Pattern, and Tool Mark Evidence Collection
7.2 Postmortem Redistribution (PMR), Vd & Toxicological Pharmacokinetics
Key Takeaways Explain This Topic AI
Postmortem redistribution (PMR) is the passive, time-dependent diffusion of drugs down concentration gradients from high-concentration organ reservoirs (liver, lungs, myocardium) into adjacent vascular spaces following somatic death.
Xenobiotics with a high volume of distribution (Vd > 3-4 L/kg), high lipophilicity, and basic pKa values are severely susceptible to PMR, leading to falsely elevated drug levels in central blood sources.
The Central-to-Peripheral (C/P) concentration ratio quantifies redistribution propensity: a C/P ratio exceeding 2.0 to 3.0 signifies marked PMR, whereas a ratio near 1.0 indicates postmortem anatomical stability.
Differentiating antemortem ethanol consumption from postmortem putrefactive fermentation requires multi-matrix triangulation across blood, vitreous humor, and urine, corroborated by testing for non-oxidative metabolites ethyl glucuronide (EtG) and ethyl sulfate (EtS).
Last updated: September 2026
Biophysical Pathophysiology of Postmortem Redistribution (PMR)
Following somatic cardiac arrest, cellular respiration and adenosine triphosphate (ATP) production instantly terminate. Within minutes, the loss of active, energy-dependent transmembrane transport systems disrupts cellular ionic equilibrium, allowing intracellular calcium, sodium, and water influx. Intracellular lysosomes swell, destabilize, and rupture, releasing potent acid hydrolases, proteases, and lipases that initiate progressive autolysis . Concurrently, vascular endothelial barriers disintegrate, and cellular tight junctions break down, transforming the body into a static biophysical system governed entirely by thermodynamic entropy and passive molecular diffusion.
Postmortem Redistribution (PMR) refers to the passive, time-dependent movement of drugs down steep concentration gradients from solid tissue reservoirs—specifically organ systems that sequester high drug masses during life (such as the lungs, liver, myocardium, and gastrointestinal mucosa)—into adjacent quiescent vascular spaces. Consequently, drug concentrations measured in blood samples harvested postmortem often do not reflect the pharmacologically active circulating concentration present at the moment of death. +------------------------------------------------------------------------------------------------+
- | ANATOMICAL VECTORS OF POSTMORTEM REDISTRIBUTION |
- +------------------------------------------------------------------------------------------------+
- HIGH-CONCENTRATION TISSUE RESERVOIR RECIPIENT VASCULAR COMPARTMENT
[ Pulmonary Parenchyma (Lungs) ] --------> [ Pulmonary Veins & Left Atrium / Ventricle ]
[ Myocardium (Heart Muscle) ] --------> [ Cardiac Chambers (Right & Left Ventricles) ]
[ Hepatic Parenchyma (Liver) ] --------> [ Inferior Vena Cava & Hepatic Veins ]
[ Gastric Mucosa / Residual Bolus ] --------> [ Left Liver Lobe, Portal Vein & Pericardium ]
- [ Mesenteric Adipose ] --------> [ Pelvic & Abdominal Venous System ]
- Cellular Mechanisms: Lysosomal Ion Trapping and Transcellular Transudation
The cellular storage of basic drugs is governed by lysosomal ion trapping . In living cells, the acidic lumen of intracellular lysosomes (pH ≈ 4.5 - 5.0) creates a steep pH gradient relative to the neutral cytosol (pH ≈ 7.2). Basic drugs (pKa > 7.4 - 9.5) readily diffuse across the lipophilic lysosomal membrane in their uncharged, unionized state. Once inside the acidic lysosomal compartment, the molecules become protonated (ionized). In their charged form, they are membrane-impermeant and become trapped at concentrations up to 1,000-fold higher than in surrounding cytoplasm. Upon somatic death and cellular autolysis, the lysosomal membranes hydrolyze, dumping massive stores of concentrated basic drugs into the cytosol, from which they passively transudate through ruptured endothelial walls into neighboring blood vessels.
Pharmacokinetic Determinants: Volume of Distribution (Vd), Lipophilicity, and pKa
Not all pharmacological agents undergo postmortem redistribution. Susceptibility to PMR is dictated by three intrinsic physicochemical and pharmacokinetic properties:
Apparent Volume of Distribution (Vd) : The theoretical volume of fluid into which the total amount of drug in the body would have to be uniformly distributed to yield the measured plasma concentration:
Vd = (Total Amount of Drug in Body) / (Plasma Drug Concentration)
Low Vd (< 1.0 L/kg) : The drug is hydrophilic, polar, or highly bound to circulating plasma albumin. It remains overwhelmingly confined to the circulating vascular compartment and extracellular water. Such agents demonstrate minimal to zero PMR . Examples include ethanol (Vd ≈ 0.6 L/kg), salicylic acid (Vd ≈ 0.15 L/kg), phenytoin (Vd ≈ 0.6 L/kg), warfarin (Vd ≈ 0.15 L/kg), and lithium (Vd ≈ 0.7 L/kg).
High Vd (> 3.0 - 4.0 L/kg) : The drug is lipophilic, poorly water-soluble, and concentrates heavily in extravascular tissue depots (adipose, lungs, brain, liver). When Vd exceeds total physiological body water (approximately 0.6 L/kg in adult humans), tissue concentrations vastly eclipse circulating blood concentrations. Such agents demonstrate profound PMR . Examples include tricyclic antidepressants (amitriptyline Vd ≈ 15 - 20 L/kg), digoxin (Vd ≈ 6 - 8 L/kg), fentanyl (Vd ≈ 4 - 6 L/kg), methamphetamine (Vd ≈ 3 - 5 L/kg), diphenhydramine (Vd ≈ 4 - 6 L/kg), and chlorpromazine (Vd ≈ 20 L/kg).
Acid-Base Chemistry (pKa) : Basic amines (pKa > 7.4) undergo extensive cellular uptake and lysosomal trapping. Conversely, acidic drugs (pKa < 5.0) remain largely ionized at physiological pH and bound to circulating albumin, resisting cellular sequestration and redistribution.
Lipophilicity (Octanol-Water Partition Coefficient, log P) : Compounds with high log P rapidly penetrate cellular lipid bilayers and concentrate in fatty organs, providing large reservoirs available for postmortem desorption.
- Pharmacological Agent Drug Class Vd (L/kg) pKa Typical C/P Ratio PMR Severity Profile
- Ethanol Aliphatic Alcohol 0.6 N/A 0.9 – 1.1 None ; highly stable; uniform body water distribution
- Salicylic Acid Acidic Analgesic 0.15 3.0 0.9 – 1.1 None ; extensively bound to circulating albumin
- Diazepam Benzodiazepine 1.1 3.4 1.0 – 1.3 Minimal ; relatively stable across collection sites
- Morphine Opioid Analgesic 3.2 8.0 1.2 – 2.2 Moderate ; mild postmortem elevation in central blood
- Cocaine Tropane Alkaloid 2.5 8.6 1.3 – 2.4 Moderate ; complicated by ongoing in vitro esterase decay
- Fentanyl Synthetic Opioid 4.0 – 6.0 8.4 1.5 – 3.0 Moderate to High ; pulmonary and muscle redistribution
- Methamphetamine Sympathomimetic 3.0 – 5.0 9.9 1.5 – 3.0 Moderate to High ; significant tissue sequestration
Amitriptyline Tricyclic Antidepressant 15.0 – 20.0 9.4 3.0 – 8.0+ Severe ; cardiac blood levels can exceed femoral by 800%
- Digoxin Cardiac Glycoside 6.0 – 8.0 N/A 2.5 – 6.0+ Severe ; profound diffusion from myocardium into blood
- The Central-to-Peripheral (C/P) Ratio: Diagnostic Interpretation
To evaluate the magnitude of redistribution for a given compound in casework, forensic toxicologists calculate the Central-to-Peripheral (C/P) Ratio :
C/P Ratio = (Drug Concentration in Central Cardiac Blood) / (Drug Concentration in Peripheral Femoral Blood)
Clinical and Investigative Rules for C/P Interpretation:
C/P ≈ 1.0 (0.8 - 1.2) : Denotes absence of significant redistribution. Blood concentrations drawn from cardiac chambers or peripheral vessels are virtually interchangeable (e.g., ethanol, carboxyhemoglobin, paracetamol/acetaminophen).
C/P Between 1.5 and 2.5 : Denotes moderate redistribution. Cardiac blood concentrations are mildly to moderately inflated. Peripheral femoral blood must be utilized for quantitative interpretation, but cardiac blood provides a reasonable backup if properly documented.
C/P > 3.0 (and up to 10+) : Denotes severe, volatile redistribution. Cardiac blood concentrations are dramatically inflated due to passive diffusion from adjacent myocardial or pulmonary parenchymal depots.
The Deadly Forensic Trap: Consider a decedent whose cardiac blood amitriptyline concentration is measured at 3.2 mg/L (a level widely recognized in clinical literature as fatal), but whose clamped femoral blood concentration is only 0.4 mg/L (a therapeutic or sub-lethal concentration). If the investigator or prosector collected only cardiac blood—or if the toxicologist analyzed cardiac blood without knowing its anatomical origin—the death would be erroneously certified as a fatal suicidal tricyclic antidepressant overdose! When the true femoral concentration is recognized, the C/P ratio of 8.0 exposes the cardiac level as a postmortem artifact, forcing the investigator to seek the real cause of death (such as subtle asphyxia or natural arrhythmia). +------------------------------------------------------------------------------------------------+
- | WORKED FORENSIC CALCULATION: AMITRIPTYLINE |
- +------------------------------------------------------------------------------------------------+
Decedent: 70 kg Adult Male found deceased in bed. History of Depression.
Toxicology Results:
- Cardiac Blood Amitriptyline: 2.80 mg/L
- Femoral Blood Amitriptyline: 0.35 mg/L
- Vitreous Humor Amitriptyline: 0.05 mg/L
Step 1: Calculate C/P Ratio:
C/P = (2.80 mg/L) / (0.35 mg/L) = 8.0
Step 2: Evaluate Pharmacokinetics:
Amitriptyline Vd = 16 L/kg; pKa = 9.4 (Highly lipophilic basic amine).
- Therapeutic Range: 0.10 - 0.25 mg/L
- Toxic Range: 0.50 - 1.00 mg/L
- Lethal Threshold: > 1.50 - 2.00 mg/L
Step 3: Medicolegal Conclusion:
The cardiac concentration (2.80 mg/L) falsely suggests massive lethal overdose.
- However, the peripheral femoral concentration (0.35 mg/L) reflects mild therapeutic
- elevation (non-lethal). The C/P ratio of 8.0 is a textbook demonstration of PMR
from massive myocardial and pulmonary drug stores into the cardiac lumen.
Amitriptyline toxicity is ruled OUT as the primary immediate cause of death.
Postmortem Microbial Ethanol Synthesis vs. Antemortem Ingestion
Ethanol is the single most common toxicological agent detected in medicolegal casework. However, identifying ethanol in a postmortem blood sample does not automatically prove that the decedent consumed alcoholic beverages prior to death. In decomposing, traumatized, or thermally injured bodies, postmortem microbial fermentation can synthesize substantial quantities of endogenous ethanol de novo.
The Fermentation Cascade
Normal enteric bacteria (Escherichia coli, Klebsiella pneumoniae, Enterobacter cloacae, Proteus mirabilis) and ubiquitous fungal yeasts (Candida albicans, Saccharomyces cerevisiae) proliferate rapidly following somatic death. As intestinal mucosal integrity fails, these microorganisms translocate through the mesenteric vasculature and portal system into the general circulation. Utilizing endogenous, unabsorbed carbohydrates (glucose, glycogen), lactate, and amino acids as metabolic substrates, these microbes produce ethanol via the anaerobic pyruvate decarboxylase and alcohol dehydrogenase pathways:
Glucose → 2 Pyruvate → 2 Acetaldehyde → 2 Ethanol + 2 CO2
Under favorable ambient temperatures (> 25°C / 77°F), putrefactive microbial synthesis can produce blood ethanol concentrations exceeding 0.08 - 0.15 g/dL (and occasionally up to 0.20 g/dL) within 48 to 72 hours in a completely sober decedent.
Diagnostic Triangulation Protocol to Verify True Antemortem Ingestion
To definitively distinguish true antemortem alcohol intake from putrefactive microbial synthesis, the forensic investigator must execute a multi-matrix analytical strategy:
Vitreous Humor Ethanol Comparison : The vitreous chamber is an avascular, sterile compartment containing minimal glucose (typically < 100 mg/dL in non-diabetics) and no resident microflora. Microbes cannot penetrate the intact eyeball during early-to-moderate decomposition. Because ethanol is completely water-soluble, it distributes across total body water. The water content of whole blood is approximately 80%, whereas vitreous humor is approximately 98% to 99% water. In the fully absorbed, post-absorptive equilibrium state, the Vitreous-to-Blood Ethanol Ratio (V/B) is approximately 1.15 - 1.25 .
Antemortem Ingestion : Blood ethanol = 0.12 g/dL; Vitreous ethanol = 0.14 g/dL. Vitreous ethanol correlates with blood ethanol based on water content. True antemortem intake is confirmed.
Microbial Synthesis : Blood ethanol = 0.10 g/dL; Vitreous ethanol = 0.00 g/dL. Zero alcohol in the protected vitreous chamber proves that the blood alcohol arose entirely from postmortem microbial fermentation.
Urine Ethanol Comparison : Urine water content is approximately 99%. In the post-absorptive phase, the Urine-to-Blood Ratio (U/B) typically averages 1.25 - 1.35 . Finding high blood alcohol with zero urine alcohol in a full bladder strongly indicates postmortem fermentation (or rapid death occurring in the ultra-early absorption phase, < 15 minutes post-ingestion).
Volatile Congener Profiling (n-Propanol Analysis) : Microbial fermentation produces a characteristic fingerprint of higher aliphatic alcohols and metabolic byproducts, specifically n-propanol , isopropanol, isobutanol, and acetaldehyde. Beverage alcohol fermentations utilized for human consumption contain virtually zero n-propanol. The detection of n-propanol alongside ethanol via headspace gas chromatography with flame ionization detection (GC-FID) serves as an objective chemical biomarker of active microbial putrefaction.
Non-Oxidative Minor Ethanol Metabolites: Ethyl Glucuronide (EtG) and Ethyl Sulfate (EtS) :
EtG and EtS are polar, non-oxidative direct metabolites of ethanol formed in trace quantities (accounting for < 0.1% of ethanol clearance). They are synthesized exclusively by human hepatic enzymes —specifically, UDP-glucuronosyltransferases (UGT) conjugate ethanol with glucuronic acid to form EtG, while sulfotransferases (SULT) conjugate ethanol with inorganic sulfate to form EtS.
Putrefactive bacteria and yeasts possess neither UGT nor human sulfotransferase pathways; microorganisms cannot synthesize EtG or EtS . Finding EtG and EtS in postmortem blood, urine, or tissue conclusively proves that human in vivo metabolism occurred prior to death, definitively verifying antemortem ethanol exposure even in moderately decomposing remains.